<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>In-situ antigen–primed systemic immunity (IAPSI) - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-25</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-25</p>
                <p><strong>Name:</strong> In-situ antigen–primed systemic immunity (IAPSI)</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why neoadjuvant-plus-adjuvant immunotherapy improves melanoma outcomes compared to adjuvant-only immunotherapy, based on the following results.</p>
                <p><strong>Description:</strong> Neoadjuvant checkpoint blockade improves outcomes over adjuvant-only therapy because initial exposure to immune therapy while the intact tumor and its draining lymphatic network are present (a) rapidly reactivates tumor-resident memory T cells (TRM) and circulating tumor-reactive clones, (b) drives dendritic cell–mediated antigen spreading, and (c) eliminates occult micrometastases during the preoperative window. These mechanisms translate into higher rates of major pathologic responses that are strongly prognostic for recurrence-free and event-free survival.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 3: Law 3</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In resectable stage III melanoma, brief (2–3 cycles) neoadjuvant PD-1 prior to surgery will increase early blood immune-response signatures (3 weeks) and correlate with post-op ctDNA clearance more frequently than adjuvant-only PD-1.</li>
                <li>Patients achieving MPR after neoadjuvant PD-1 ± LAG-3 will exhibit expansion of pre-existing TRM clonotypes in blood and skin that persist at 1 year, correlating with low recurrence.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Sequentially alternating short neoadjuvant PD-1 then surgery, followed by adjuvant PD-1 escalation only for ctDNA-positive patients, will match EFS of continuous perioperative PD-1 while reducing total exposure.</li>
                <li>In ultra-high tumor-burden nodal disease, a single priming dose of PD-1 (vs immediate surgery) will still improve EFS, provided surgery occurs within 3 weeks; magnitude uncertain.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>A randomized trial showing identical EFS between neoadjuvant+adjuvant and adjuvant-only PD-1 with identical total dosing and follow-up would refute the timing advantage law.</li>
                <li>If early TRM/circulating activation signatures at 2–3 weeks after neoadjuvant PD-1 fail to correlate with pathologic response or EFS, the mechanistic priming claim would be weakened.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Direct causal linkage between specific TRM subclusters (e.g., TOX vs IFNG) and human neoadjuvant pathologic response strength remains inferential. <a href="../results/extraction-result-21.html#e21.5" class="evidence-link">[e21.5]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>